Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease

USA - English

News provided by

Oct 27, 2023, 07:00 ET

Clario's Precision Motion Opal^® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.
Digital endpoints of gait and balance, captured during a 2-Minute Walk test and 30-second Sway test, identify significant motor symptom progression more rapidly than conventional clinical rating scales.
Earlier detection supported by state-of-the-art sensor technology and machine learning is a promising discovery to aid in the expedited development of effective PD treatments.

PHILADELPHIA, Oct. 27, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, today announced that the application of Opal^® wearable sensor technology (legacy APDM, Inc.), with advisory from Precision Motion scientists, has helped the University of Oxford researchers develop a new understanding of motor symptom progression in Parkinson's Disease, offering promising implications for neuroscience clinical trials and future treatments.

Through a comprehensive study leveraging Clario's wearable sensors and machine learning, researchers were able to track the motor symptom progression in individuals with Parkinson's Disease (PD) better than the conventionally used clinical rating scales. Importantly, they found that the wearable technology detected disease progression in a significantly shorter timeframe than the traditional method.

Clario's scientific and technical expertise empowered the reliable collection of precise digital endpoints of movement enabling earlier detection of disease progression. This ultimately should accelerate the development of new medicines for PD, and potentially allow for earlier intervention for patients afflicted with this debilitating condition.

The University of Oxford study, led by Chrystalina Antoniades, Associate Professor of Neuroscience, Clinical Neurology, is a part of the Oxford Quantification in Parkinsonism (OxQUIP) project, in which Clario's Precision Motion Opal wearable sensors have been deployed to capture motor impairment in both PD and Progressive Supranuclear Palsy (PSP).

"We are honored to support Professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field," said Kristen Sowalsky, PhD, DC, VP of Medical & Scientific Affairs. "This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson's Disease progression more accurately and assess the efficacy of early therapeutic intervention. The potential impact of these findings for neuroscience clinical trials is outstanding."

"Time is crucial in clinical trials," said Professor Antoniades, Associate Professor of Neuroscience, Clinical Neurology at the University of Oxford. "If we can tell whether a treatment is working earlier, we can speed up its translation. It is also important to be able to tell rapidly which things are not working, so we can divert resources to more promising targets."

For direct inquiries, please contact [email protected].

For more information or to speak to a specialist about Clario's Precision Motion data endpoint collection and its ability to transform clinical trials please go to https://clario.com/solutions/precision-motion/.

About Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario's global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over five million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, go to Clario.com or follow us on LinkedIn and Twitter

Clario Media Contact
Duncan Cantor
Sr. Director, Corporate Communications
[email protected]

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg